Drug intelligence / Profile preview

TPC + tislelizumab

Development stage: Unknown
Lead developer: BeiGene
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

TPC + tislelizumab is a combination therapy consisting of the TPC regimen (cisplatin, nab-paclitaxel, and capecitabine) combined with tislelizumab, an anti-PD-1 antibody. This combination is being investigated in clinical trials for the treatment of nasopharyngeal carcinoma with bone metastasis. Tislelizumab is designed to bind to PD-1 with high affinity, blocking the interaction between PD-1 and its ligands, thereby restoring the anti-tumor immune response.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on TPC + tislelizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPC + tislelizumab.

Explore the full profile